Page 35 - Amgen News Today

Argus Investors Counsel Inc. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.3% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,638 shares of the medical research company’s stock after selling 648 shares during the quarter. Argus Investors Counsel Inc.’s holdings in Amgen were worth $1,603,000 as of […]

Welcome to this issue of The Precedent, which covers those opinions from Q3 and Q4 of 2023 that the Federal Circuit designated as precedential and worthy of publication in the Federal Reporter.

Amgen headquarters in Thousand Oaks. (file photo) Thousand Oaks-based Amgen has received approval from the U.S. Food and Drug Administration for its treatment, Imdelltra, which is used on adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Announced May 16, Amgen said in a press release that Imdelltra

Welcome to Marks & Clerk's new series of articles regarding the nature and role of data in the patent system. This current article is intended to serve as an introduction to the series...

Recent news from NewsTalk Florida. Click here to get details.

BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood

The significant growth in the ambulatory surgical centers market can be credited to several factors highlighting the rising need for multispecialty outpatient surgical facilities. A primary

SAN DIEGO — Among patients with moderate to very severe COPD receiving tezepelumab vs. placebo, the annualized rate of exacerbations dropped by 17%, according to research presented at the American Thoracic Society International Conference.“Tezepelumab is a monoclonal antibody that specifically blocks [thymic stromal lymphopoietin] from interacting with its receptor,” Dave Singh,

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.